SUNNYVALE, Calif., Dec. 17, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Accuray Exchange in Radiation Oncology (AERO™) Users' Meeting was held November 13-14, 2015 at the University of North Carolina at Chapel Hill Friday Center for Continuing Education in Chapel Hill, North Carolina. The event attracted radiation oncologists, physicists and therapists from the United States who engaged in peer-to-peer discussions about innovation in cancer treatments, including recent developments with the CyberKnife® and TomoTherapy® Systems.
"Accuray created this forum for CyberKnife and TomoTherapy users to exchange ideas and experiences that can help shape clinical decisions, drive practice efficiencies and improve patient outcomes," said Joshua H. Levine, president and chief executive officer of Accuray. "By identifying best practices, physicians are better equipped to maximize the advanced features of our technology that enable highly customized and precise treatment plans to be delivered for almost all tumor types. Based on the positive response we received from meeting attendees, we plan to host another Users' Meeting April 10-11, 2016, in San Francisco immediately following the UCSF radiation oncology meeting titled, 'UCSF Radiation Oncology: Precision Radiation Oncology.'"
More than two dozen specialized breakout sessions were led by 19 physicians and physicists. The sessions focused on topics including the state-of-the-art technology in oncology, cutting-edge CyberKnife System and TomoTherapy System clinical research, practical physics education, and more. Some additional Users' Meeting highlights included:
- A workshop about incorporating human factors analysis into radiation therapy practices
- Interactive discussion about clinical innovations, new technologies and operational efficiencies
- A keynote address on the application of engineering principles to improve quality and safety in SBRT and IMRT
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Further information on Accuray, the CyberKnife® and TomoTherapy® Systems is available at www.accuray.com.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's report on Form 10-Q, filed on November 5, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated